Jefferies Cuts Estimates But Lifts PT on The Medicines Co (MDCO) Post Q4

February 21, 2013 12:17 PM EST
Get Alerts MDCO Hot Sheet
Price: $35.47 -1.53%

Rating Summary:
    15 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade MDCO Now!
Join SI Premium – FREE
Jefferies raised its price target on Buy-rated The Medicines Company (NASDAQ: MDCO) from $34 to $36 following a beat on the top and bottom line for Q4 on higher WW Angiomax sales. Guidance was generally in-line.

Commenting, the analyst states: "Notably, 2013 is catalyst-rich with data flow including PHOENIX data presentation and SOLO-2 topline results with at least three regulatory filings to potentially drive long-term topline growth and diversification."

The firm cut FY13 EPS from $1.38 to $0.85 and FY14 from $1.78 to $1.34.

For an analyst ratings summary and ratings history on The Medicines Company click here. For more ratings news on The Medicines Company click here.

Shares of The Medicines Company closed at $32.57 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment